Theratechnologies ( (TSE:TH) ) has provided an announcement.
Theratechnologies reported a strong first quarter for 2025, with a 17% increase in total revenue year-over-year, reaching $19 million. The company received FDA approval for EGRIFTA WR™, a new formulation to treat excess visceral abdominal fat in adults with HIV and lipodystrophy, which is expected to drive future growth. Despite a temporary supply disruption for EGRIFTA SV®, the company resumed distribution and anticipates a one-time revenue impact of $10 to $12 million for the fiscal year. The approval of a Prior Approval Supplement by the FDA allows for regular distribution of EGRIFTA SV®, strengthening the company’s market position.
Spark’s Take on TSE:TH Stock
According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.
Theratechnologies faces significant challenges with profitability and high financial leverage, which weigh heavily on the stock’s attractiveness. While there are noteworthy improvements in EBITDA and strategic partnerships, these are overshadowed by technical and valuation weaknesses. Investors should be cautious and monitor ongoing operational adjustments and financial stability improvements.
To see Spark’s full report on TSE:TH stock, click here.
More about Theratechnologies
Theratechnologies Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies. The company primarily targets the treatment of HIV-related conditions, with key products including EGRIFTA SV® and Trogarzo®.
YTD Price Performance: -15.76%
Average Trading Volume: 1,079,607
Technical Sentiment Signal: Buy
Current Market Cap: $76.01M
For a thorough assessment of TH stock, go to TipRanks’ Stock Analysis page.